Impact of cancer diagnosis on persistence of oral antidiabetic drugs
| dc.rights.license | open | en_US |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | LETINIER, Louis | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MANSIAUX, Yohann | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | PARIENTE, Antoine
IDREF: 13395711X | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | FOURRIER-REGLAT, Annie | |
| dc.date.accessioned | 2020-11-30T11:23:41Z | |
| dc.date.available | 2020-11-30T11:23:41Z | |
| dc.date.issued | 2018-05 | |
| dc.identifier.issn | 1872-8227 (Electronic) 0168-8227 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/21259 | |
| dc.description.abstractEn | AIMS: The purpose of this study was to determine the effects of cancer occurrence on persistence of oral antidiabetic drugs (OAD) in France. METHODS: A retrospective cohort including incident OAD users between 2006 and 2011 was set up using a permanent sample of health insurance beneficiaries (Echantillon Generaliste de Beneficiaires, EGB). A Cox model was used to assess the association between cancer occurrence and OAD persistence. Non-persistence was defined as a gap in OAD treatment coverage between the end of a given prescription and a new one greater than or equal to 90 days. Cancer occurrence was studied as a time-dependent variable. RESULTS: The study included 13,943 OAD users. Median follow-up was 760 days. After adjustment for age, sex, first OAD used, type of prescriber and polypharmacy, non-persistence risk was higher after a diagnosis of cancer: (HR: 1.93 and IC 95% 1.69; 2.21). Subgroup analyses according to cancer localization found a higher risk of non-persistence for lung cancer (HR: 2.66 and IC 95% 1.68; 4.23) and colorectal cancer (HR: 2.02 and IC 95% 1.40; 2.91). CONCLUSIONS: Our findings indicate there is an association between cancer diagnosis and OAD non-persistence. Additional studies of this type would be useful to evaluate the association between cancer diagnosis and persistence of treatment of other chronic diseases. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | PharmacoEpi-Drugs | |
| dc.title.en | Impact of cancer diagnosis on persistence of oral antidiabetic drugs | |
| dc.title.alternative | Diabetes Res Clin Pract | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.diabres.2018.03.011 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 29526679 | en_US |
| bordeaux.journal | Diabetes Research and Clinical Practice | en_US |
| bordeaux.page | 323-330 | en_US |
| bordeaux.volume | 139 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | PharmacoEpi-Drugs | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03193175 | |
| hal.version | 1 | |
| hal.date.transferred | 2021-04-08T13:46:56Z | |
| hal.export | true | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Diabetes%20Research%20and%20Clinical%20Practice&rft.date=2018-05&rft.volume=139&rft.spage=323-330&rft.epage=323-330&rft.eissn=1872-8227%20(Electronic)%200168-8227%20(Linking)&rft.issn=1872-8227%20(Electronic)%200168-8227%20(Linking)&rft.au=LETINIER,%20Louis&MANSIAUX,%20Yohann&PARIENTE,%20Antoine&FOURRIER-REGLAT,%20Annie&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||